Tryp Therapeutics Inc. (TRYPF)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. James S. Kuo M.B.A., M.D. | Co-Founder & Director | 19.49k | -- | 1965 |
| Mr. Peter Molloy ASIP, B.A., C.F.A. | Chief Business Officer & Director | 134.16k | -- | 1972 |
| Mr. Jason Carroll | CEO & Director | -- | -- | -- |
| Dr. James P. Gilligan MSIB, Ph.D. | President & Chief Scientific Officer | 230.83k | -- | 1952 |
| Dr. William James Garner M.D., M.P.H., MPH | Founder & MD | 41.24k | -- | 1966 |
| Mr. Jim O'Neill | Chief Financial Officer | -- | -- | -- |
| Mr. Sidney Taubenfeld R.Ph | Chief Operating Officer | 35.59k | -- | -- |
| Ms. Joy Willis | Director of Investor Relations | -- | -- | -- |
| Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D. | Chief Medical Officer | -- | -- | 1949 |
Tryp Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company's program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.
Corporate Governance
Recent Events
Recent Events Information Not Available
Upcoming Events
Upcoming Events Information Not Available